Regeneron
Regeneron Pharmaceuticals, Inc., commonly referred to as Regeneron, is a leading biotechnology company headquartered in the United States. Founded in 1988, Regeneron has established itself as a pioneer in the development of innovative medicines, particularly in the fields of ophthalmology, oncology, and immunology. With a strong focus on research and development, Regeneron is renowned for its unique products, including EYLEA® for eye diseases and Dupixent® for various allergic conditions. The company’s commitment to scientific excellence has positioned it as a key player in the biopharmaceutical industry, achieving significant milestones such as the rapid development of treatments during public health emergencies. Regeneron continues to expand its global footprint, with major operations across North America and Europe, solidifying its reputation as a leader in advancing healthcare solutions.
DitchCarbon Score
How does Regeneron's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Regeneron's score of 54 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Regeneron's reported carbon emissions
In 2024, Regeneron reported total greenhouse gas emissions of approximately 1,465,520,000 kg CO2e, with Scope 1 emissions at about 80,300,000 kg CO2e, Scope 2 emissions at approximately 40,400,000 kg CO2e (market-based), and Scope 3 emissions reaching about 1,344,820,000 kg CO2e. The previous year, 2023, saw total emissions of about 972,376,000 kg CO2e, with Scope 1 at approximately 69,600,000 kg CO2e, Scope 2 at about 29,900,000 kg CO2e (market-based), and Scope 3 at around 872,876,000 kg CO2e. Regeneron has set ambitious climate commitments, aiming to reduce its combined Scope 1 and 2 greenhouse gas emissions per square metre by 30% by 2025, using a 2016 peak baseline. This target applies to both Scope 1 and Scope 2 emissions. Furthermore, the company plans to match 100% of its electricity consumption with certified renewable energy sources by 2035, which will encompass both Scope 1 and Scope 2 emissions. Overall, Regeneron's commitment to reducing its carbon footprint reflects a proactive approach to sustainability, aligning with industry standards and climate action goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 58,200,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 27,800,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 394,571,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Regeneron is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
